Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Lung Cancer
Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00075517
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 12 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Anxiety Disorder, Depression
Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This trial is designed to test the efficacy of fluoxetine to improve patient's quality of life during chemotherapy. An innovative application of a selective serotonin reuptake inhibitor may modulate the effects of fatigue…
- Conditions
- Anxiety Disorder, Depression, Fatigue, Lung Cancer
- Trial name
- NCT00005850
- Testing
- cisplatin, fluoxetine, gemcitabine hydrochloride
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer, Melanoma (Skin)
ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 3521 in treating patients who have advanced…
- Trial name
- NCT00003989
- Testing
- ISIS 3521
- Where
- 27 sites in Austria, Belgium and 7 more
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer, Nonsmall Cell
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.
- Trial name
- NCT06319950
- Testing
- Furmonertinib, Osimertinib
- Volunteers
- 255 people
- Sponsor
- Taizhou Hospital
NSCLC Stage IV
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients
A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab (Anti-PD-1 Humanized Monoclonal Antibody Injection) and Chemotherapy in Previously…
- Trial name
- NCT05787613
- Testing
- HLX26, Serplulimab, Chemotherapy drug
- Where
- 3 sites in China
- Volunteers
- 132 people
- Sponsor
- Shanghai Henlius Biotech
Non Small Cell Lung Cancer, Lung Cancer Stage III
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer
Single arm, Phase II trial of concurrent Durvalumab (MEDI 4736) and radiotherapy followed by consolidative Durvalumb (MEDI 4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT04003246
- Testing
- Thoracic RT and Durvalumab, Consolidative Durvalumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Texas Southwestern Medical Center
Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
The goal of this clinical trial is to compare the amount of study drug in patients' blood to confirm that SB27 works in the same way as EU and US sourced Keytruda in early or locally advanced non-small cell lung cancer (NSCLC)…
- Trial name
- NCT06268613
- Testing
- SB27, EU sourced Keytruda, US sourced Keytruda
- Where
- 24 sites in Poland, South Korea and 2 more
- Volunteers
- 163 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Non-small Cell Lung Carcinoma
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
This is a multicenter, randomized, open label, phase III study.
- Trial name
- APEX (NCT04762459)
- Testing
- Almonertinib, Pemetrexed, Cisplatin
- Where
- 34 sites in China
- Volunteers
- 606 people
- Sponsor
- Chinese Academy of Medical Sciences
Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
This phase I trial finds out the best dose, possible benefits and/or side effects of papaverine when given together with chemoradiation intreating patients with stage II-III non-small cell lung cancer.
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
- Trial name
- NCT05136846
- Testing
- Carboplatin, Durvalumab, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer
TG4010 and Nivolumab in Patients With Lung Cancer
This phase II trial studies how well TG4010 and nivolumab work in previously treated patients with non-small cell lung cancer. Vaccines that are made from a gene-modified virus, such as TG4010, may help the body build an…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
- Trial name
- NCT02823990
- Testing
- TG4010, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Megan Daly, MD
Lung Cancer
Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033410
- Testing
- carboplatin, paclitaxel, tirapazamine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- California Cancer Consortium
Carcinoma, Non-Small-Cell Lung
A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer
This study is intended to evaluate the role of paclitaxel poliglumex and carboplatin in the treatment of unresectable Stage III non-small cell lung cancer along with radiation therapy in a multi-institutional trial.
- Trial name
- NCT00352690
- Testing
- Paclitaxel poliglumex, Carboplatin, External beam radiation therapy
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Lung Cancer
Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00398385
- Testing
- cisplatin, gemcitabine hydrochloride, adjuvant therapy
- Where
- South Korea
- Volunteers
- 170 people
- Sponsor
- National Cancer Center, Korea
Non-Small Cell Lung Cancer
Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer
A randomized phase II study to assess the efficacy and safety of Trastuzumab Rezetecan and/or Adebrelimab as consolidation therapy following chemoradiotherapy in patients with unresectable stage III HER2-altered NSCLC.
- Trial name
- NCT07836543
- Testing
- Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab, Trastuzumab Rezetecan (SHR-A1811), Adebrelimab
- Volunteers
- 105 people
- Sponsor
- Ming Chen
NSCLC
Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)
This is a single-center, single-arm, phase 2 trial evaluating the efficacy and safety of retlirafusp alfa combined with single-agent chemotherapy as neoadjuvant treatment for patients with resectable stage II-III EGFR/ALK…
- Trial name
- NCT07550920
- Testing
- Drug: Retlirafusp alfa, Drug: Single-agent Chemotherapy, Procedure: Radical Surgery
- Volunteers
- 18 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with advanced non-small cell…
- Trial name
- NCT00416650
- Testing
- erlotinib hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
This phase II trial studies how well pembrolizumab works in preventing lung cancer patients with stage I-II non-small cell lung cancer or high-risk pulmonary nodules.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8
- Trial name
- NCT03634241
- Testing
- Pembrolizumab, Quality-of-Life Assessment, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer, Respiratory Tract Neoplasm
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
This is a randomized, phase II, multi-centre clinical trial. Sample size: 68 patients (Experimental Arm (Durvalumab + chemotherapy + FMT capsules): 34 patients, Control Arm (Durvalumab + chemotherapy): 34 patients) Population…
- Trial name
- MIGRANT (NCT07247786)
- Testing
- Biological: Fecal Microbiota Transplantation, Durvalumab, Paclitaxel
- Where
- 20 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Fundación GECP
Non-Small Cell Lung Cancer
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab…
- Trial name
- NCT00343291
- Testing
- Cetuximab, Bevacizumab, Paclitaxel
- Where
- 43 sites in United States
- Volunteers
- 121 people
- Sponsor
- Eli Lilly and Company
EGFR Gene Mutation, Nonsmall Cell Lung Cancer
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
This is a study for patients with advanced non-small cell lung cancer with changes to their cancer cells called EGFR mutations. Mutated EGFR is important in the growth of cancer cells.
- Trial name
- NCT02954523
- Testing
- Dasatinib, Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Chul Kim